Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giotrif in Advanced Solid Tumors with HER Gene Aberrations
NCT02506517Phase 2Completed
- Sponsor
- University Health Network
- Start
- Aug 2015
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in solid tumor, sponsored by University Health Network. Primary endpoints: Complete Response at 2 years and Partial Response at 2 years. Started Aug 2015; status: completed.
02
Drugs
afatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02506517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506517.